tiprankstipranks
Painreform Ltd. (PRFX)
:PRFX
US Market
Holding PRFX?
Track your performance easily

PainReform (PRFX) Stock Price & Analysis

202 Followers

PRFX Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical OutcomesPatients were found to experience proper wound healing with no abnormalities in scar formation.
Product DevelopmentPRF-110 is being developed to compete with Exparel and Zynrelef, the two leading nonopioid therapies for post-operative pain.
Safety And EfficacyThe pharmacokinetic evaluations showed levels of ropivacaine in the blood were 10x lower than the levels required for toxic exposure, further supporting PRF-110’s safety.
Bears Say
Capital RequirementsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Financial PerformanceThere is uncertainty about PainReform's ability to continue the development of PRF-110 due to capital constraints and lower revenue potential.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.22%99.78%
Insiders
0.22%
Mutual Funds
― Other Institutional Investors
99.78% Public Companies and Individual Investors

PRFX FAQ

What was Painreform Ltd.’s price range in the past 12 months?
Painreform Ltd. lowest stock price was $1.73 and its highest was $69.03 in the past 12 months.
    What is Painreform Ltd.’s market cap?
    Painreform Ltd.’s market cap is $2.77M.
      When is Painreform Ltd.’s upcoming earnings report date?
      Painreform Ltd.’s upcoming earnings report date is Feb 28, 2025 which is in 50 days.
        How were Painreform Ltd.’s earnings last quarter?
        Currently, no data Available
        Is Painreform Ltd. overvalued?
        According to Wall Street analysts Painreform Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Painreform Ltd. pay dividends?
          Painreform Ltd. does not currently pay dividends.
          What is Painreform Ltd.’s EPS estimate?
          Painreform Ltd.’s EPS estimate is -7.68.
            How many shares outstanding does Painreform Ltd. have?
            Painreform Ltd. has 874,862 shares outstanding.
              What happened to Painreform Ltd.’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Painreform Ltd.?
              Currently, no hedge funds are holding shares in PRFX
              ---

              Company Description

              Painreform Ltd.

              PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
              ---
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis